Communication to the editor: Relapse of experimental autoimmune encephalomyelitis after discontinuation of FTY720 (Fingolimod) treatment, but not after combination of FTY720 and pathogenic autoantigen

DOI Web Site Web Site PubMed 被引用文献5件 参考文献20件
  • Yoshida Yuya
    Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, Setsunan University
  • Tsuji Takumi
    Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, Setsunan University
  • Fujita Tetsuro
    Research Institute for Production and Development
  • Kohno Takeyuki
    Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, Setsunan University Research Institute for Production and Development

書誌事項

タイトル別名
  • Relapse of Experimental Autoimmune Encephalomyelitis after Discontinuation of FTY720 (Fingolimod) Treatment, but Not after Combination of FTY720 and Pathogenic Autoantigen

この論文をさがす

抄録

FTY720 (Fingolimod) is known to have a significant therapeutic effect on experimental autoimmune encephalomyelitis (EAE). Here, we used an EAE mouse model, which had been established by immunizing C57BL/6J mice with a partial peptide of myelin oligodendrocyte glycoprotein (MOG35—55), to examine the relapse of EAE upon discontinuation of treatment with FTY720 alone or in combination with MOG35—55. Relapse was confirmed to occur in all animals (n=6) within one week after discontinuation of FTY720, with increase in the number of lymphocytes infiltrating the spinal cord and demyelination. However, in the case of combination therapy with FTY720 and MOG35—55, relapse following discontinuation of treatment was completely suppressed. The autoantigenic peptide might serve to suppress the clonal selection of relapse-associated autoantigen-specific T cells.

収録刊行物

被引用文献 (5)*注記

もっと見る

参考文献 (20)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ